Healthcare

AnteoTech wins initial EU approval for new Covid-19 RAT design

Wed 18 May 22, 11:39am (AEST)
Tick

Stocks in article

ado
MktCap:
-

Share article

Key Points

  • AnteoTech has seen its multi-use Covid-19 RAT design registered in the EU
  • Re-usable product efficacy now subject to ongoing trial in European jurisdictions
  • Company expects to stop selling its 1st-gen nasopharyngeal test kits

AnteoTech Limited (ASX:ADO) soared this morning in the first hour of trades by over 30% as the company announced it has registered a new covid-19 Rapid Antigent Test (RAT) design in Europe. 

AnteoTech notes that its new RAT model, dubbed EuGeni COVID-19 RAT, has thus received "regulatory approval" in the EU. 

The new registration, the company notes, is for the same core SARS-CoV-2 Ag Rapid Diagnostic Test registered in April last year, "but now covers multiple use claims to include combined nose and throat sampling," and, "nasal mid-turbinate sampling on top of the original nasopharyngeal sampling method." 

(Source: WHO) A global snapshot of Covid-19 cases by jurisdiction as of 18 May 2022
(Source: WHO) A global snapshot of Covid-19 cases by jurisdiction as of 18 May 2022

EU clinical trial underway

A European Clinical Trial is currently underway to evaluate the updated multi-use claim, which enables customers to choose their preferred method of self-led sample collection. 

AnteoTech is to phase out its nasopharyngeal test on the back of expected rising demand for its EuGeni COVID-19 RAT. 

Readers should note the nasopharyngeal testing is the invasive swab which, in layman’s terms, goes all the way up the back of the nose.

All about Omicron, for now 

The new EU registration comes on the back of trans-Atlantic analytical and clinical performance evaluations conducted between the US and the UK. 

Those evaluations specifically examined the efficacy of the new test design in detecting the Omicron variant, which has by far become the dominant colonising variant globally. 

Approvals awarded to AnteoTech's new design in Europe fall under the Vitro Diagnostic Directive (IVDD) 98/79/EC Regulations. 

The World Health Organisation remains on-alert for the evolution of new covid-19 variants. 

AnteoTech's three monthly chart reveals the spike in market interest this morning
AnteoTech's three monthly chart reveals the spike in market interest this morning

 

Written By

Jonathon Davidson

Journalist

Jonathon is a journalism graduate and avid market watcher with exposure to governance, NGO and mining environments. He was most recently hired as an oil and gas specialist for a trade publication.

Get the latest news and media direct to your inbox

Sign up FREE